Detailed Narrative
Q2 & H1 FY25 Performance Overview
India Glycols reported a strong financial performance for Q2 and H1 FY25. In Q2 FY25, Net Revenue grew 24% YoY to INR 961 crores, and PAT increased 31% YoY to INR 50 crores. H1 FY25 consolidated Net Sales were up 31.9% to INR 1,930 crores, with consolidated EBITDA growing 17% to INR 248 crores. The company's overall EBITDA margin for Q2 FY25 was 12.4%, a slight dip from 13.5% in the prior year, attributed to various segment dynamics.
Biofuels Segment Drives Top-line Growth
The biofuels segment was a significant growth driver, with net revenue increasing by 194% to INR 499 crores in H1 FY25, and EBIT soaring 281% to INR 32 crores. India's ethanol blending program is progressing well, with targets of 15% for 2023-24 (currently at 14.2%), 17-18% for 2024-25, and 20% for 2025-26. The company has an installed biofuels manufacturing capacity of 450 KLPD in Kashipur and expects continued demand growth, supported by government policies.
Potable Spirits Business Expansion and Amrut Partnership
The Potable Spirits business recorded a 21% growth in H1 FY25, reaching INR 551 crores. This growth was fueled by strong performance in Branded Country Liquor in Uttarakhand and IMFL in Delhi & UP, and paramilitary segments. The company has introduced Amrut brands, manufacturing and marketing them in select regions, which is seen as a significant milestone. India Glycols is the sole producer of Tetra Pack country liquor in Uttarakhand, holding an 80% market share in this format.
Specialty Chemicals & Green Chemistry Initiatives
The biobased specialty chemicals business achieved INR 369 crores in Q2 FY25. New products from the specialty chemicals plant are expected to generate over INR 100 crores in FY25, with management envisioning a potential for 5x to 10x growth in a few years. The company is focusing on sustainable and value-added products, including bio-based amines and carbon smart products, and collaborating with global partners like Stepan, Neuron, and Lanza. Despite the time required to build these businesses, the pipeline is strong.
Ennature Biopharma: Margin Pressures and Strategic Response
Ennature Biopharma's revenue grew 19% to INR 118 crores in H1 FY25, marking its best-ever quarter in terms of sales. However, the segment faces continuous price pressures on key products like Thiocolchicoside and nicotine, leading to margin distress. Management's strategy involves growing volumes, reducing costs, and focusing on higher-value derivatives and branded nutraceuticals. Efforts are also underway to meet international regulatory specifications for market access in the U.S. and Europe.
Capital Expenditure and Debt Management
The company's capital expenditure for the 100 KLPD Kashipur and 180 KLPD Gorakhpur biofuels plants totals INR 260-270 crores. The Kashipur plant is complete, and the Gorakhpur plant is expected to be fully completed by March 31st, 2025, with its grain distillery starting in Q3 FY25. Long-term debt is projected to be around INR 1,200 crores by March 31st, with a target payment of INR 200 crores next year. The cost of funds is currently around 9.8%, and the company aims to reduce it.
Cost Reduction and Sustainability Efforts
India Glycols is actively pursuing strategic cost reduction projects, with identified energy savings exceeding INR 25 crores per year. These initiatives include technological advancements, operational efficiency improvements, and exploring green energy sources like wind, solar, and hybrid solutions. The company is also evaluating various feedstocks for alcohol technology, including corn, to optimize costs and improve margins, alongside premiumization efforts in its liquor segment.